PRUXELUTAMIDE
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc,Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
252 Active assets in the Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BBB |
Fluciclovine VA Greater Los Angeles Healthcare System | Phase 4 | BBB |
LEUPROLIDE Mayo Clinic | Phase 4 | BBB |
Abiraterone Acetate Mayo Clinic | Phase 4 | BB |
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PRUXELUTAMIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →